Medication info
Stajet Tablet 2/10 mg (Pitavastatin Calcium, Ezetimibe)

Stajet Tablet 2/10 mg (Pitavastatin Calcium, Ezetimibe)

Prescription medicationTabletOral
Ingredient · strength
Pitavastatin Calcium›2mg / 1 tabletEzetimibe›10mg / 1 tablet
Manufacturer / importer
Hanlim Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202301668 · Approved 2023.05.25 · Insurance code 645306980

Summary

Main use
Improvement of primary hypercholesterolemia and mixed dyslipidemia
Who takes it
Adults
Adult dose
Administer this medicine once daily, regardless of meals. Patients should continue to follow a standard cholesterol-lowering diet before and during treatment with this medicine. The dose of this medicine should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response. The recommended initial dose is 2/10mg once daily. If the reduction in LDL cholesterol is insufficient, the dose may be increased up to a maximum of 4/10mg daily. Adjust the dose as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response. Patients taking pitavastatin calcium and ezetimibe concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Administration in patients with hepatic impairment: Because an initial dose of 1 milligram of pitavastatin calcium is recommended for patients with hepatic impairment, this medicine (a combination of pitavastatin calcium/ezetimibe) is not recommended for initial treatment. The maximum dose is 2/10mg daily. Use of this medicine (a combination of pitavastatin calcium/ezetimibe) is not recommended in patients with moderate hepatic impairment. Do not administer this medicine (a combination of pitavastatin calcium/ezetimibe) to patients with severe hepatic impairment.

Ingredients

Manufacturer
Hanlim Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of primary hypercholesterolemia and mixed dyslipidemia

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
  • elevated total cholesterol
  • elevated LDL cholesterol
  • elevated Apo B protein
  • elevated triglycerides
  • elevated non-HDL cholesterol
View approved original text

This medication is used for the treatment of primary hypercholesterolemia, particularly heterozygous familial and non-familial forms, as well as mixed dyslipidemia patients. This drug helps lower total cholesterol, LDL cholesterol, Apo B protein, triglycerides, and non-HDL cholesterol levels, aiding in the improvement of blood lipids. Furthermore, it increases the levels of high-density lipoprotein (HDL) cholesterol, which assists in promoting cardiovascular health. By taking it in conjunction with a diet, effective management of blood lipid concentrations can be achieved. This medicine plays a role in balancing blood lipids, thus lowering the risk of cardiovascular diseases.

How to take

Adult dose

Administer this medicine once daily, regardless of meals. Patients should continue to follow a standard cholesterol-lowering diet before and during treatment with this medicine. The dose of this medicine should be adjusted according to the patient's baseline LDL cholesterol level, recommended treatment goal, and response. The recommended initial dose is 2/10mg once daily. If the reduction in LDL cholesterol is insufficient, the dose may be increased up to a maximum of 4/10mg daily. Adjust the dose as appropriate at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response. Patients taking pitavastatin calcium and ezetimibe concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Administration in patients with hepatic impairment: Because an initial dose of 1 milligram of pitavastatin calcium is recommended for patients with hepatic impairment, this medicine (a combination of pitavastatin calcium/ezetimibe) is not recommended for initial treatment. The maximum dose is 2/10mg daily. Use of this medicine (a combination of pitavastatin calcium/ezetimibe) is not recommended in patients with moderate hepatic impairment. Do not administer this medicine (a combination of pitavastatin calcium/ezetimibe) to patients with severe hepatic impairment.

Precautions

This medication should not be used in certain patients. For instance, patients with allergies to its components, those with active liver disease, severe liver dysfunction, or any issues with bile drainage should not take it. Additionally, this drug should not be used by patients currently taking immunosuppressants like cyclosporine, patients with myopathies, pregnant women or those who may become pregnant, breastfeeding women, and children. This medication contains lactose, so it should not be given to patients with lactose intolerance. Patients with renal or liver dysfunction, those with a history of liver disease, excessive alcohol consumption, hypothyroidism, and the elderly should use this medication with caution. In particular, patients with a history of muscle-related diseases or muscle weakness should consult a doctor immediately if symptoms like muscle pain or weakness occur during treatment. Regular liver function tests should be performed during treatment with this medication, and if there is an increase in liver enzyme levels or symptoms such as muscle pain, weakness, or darkening of urine occur, the medication should be discontinued immediately, and medical consultation should be sought. Moreover, this medication can interact with other drugs, so patients should definitely inform their doctor or pharmacist about any medications currently being taken. Care should be taken, especially when used in conjunction with cyclosporine, fibrates, niacin, and erythromycin, as this may increase the risk of muscle damage. Pregnant or breastfeeding women should not take this medication, and women planning to become pregnant or who may conceive should consult their doctor before use. The safety and efficacy in children have not been established, and therefore, it should not be administered to pediatric patients. In case of an overdose, since there is no specific antidote, appropriate treatment and supportive care should be provided based on the symptoms, and liver function and muscle-related tests should be conducted. Finally, this medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

  • Abdominal pain
  • diarrhea
  • dry mouth
  • abdominal distension
  • gastroesophageal reflux disease
  • toothache
  • increased blood creatine phosphokinase
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weakness
Show 104 more
  • chest discomfort
  • fatigue
  • myalgia
  • urticaria
  • dizziness
  • decreased appetite
  • insomnia
  • shortness of breath
  • headache
  • altered taste
  • lightheadedness
  • sensory impairment
  • constipation
  • dryness
  • rash
  • itching
  • lethargy
  • paralysis
  • thrombocytopenia
  • increased bilirubin
  • increased cholinesterase
  • increased γ-GT
  • increased ALP
  • increased LDH
  • rigidity
  • drowsiness
  • dry throat
  • dyspepsia
  • abdominal bloating
  • stomatitis
  • vomiting
  • decreased appetite
  • glossitis
  • nausea
  • gastrointestinal discomfort
  • thrombocytopenia
  • granulocytopenia
  • leukopenia
  • eosinophilia
  • leukocytosis
  • increased globulin
  • anemia
  • increased urination
  • increased BUN
  • elevated serum creatinine
  • decreased aldosterone
  • increased aldosterone
  • increased adrenocorticotropic hormone
  • increased cortisol
  • decreased testosterone
  • muscle cramping
  • increased myoglobin
  • palpitations
  • skin pain
  • burning sensation
  • arthralgia
  • edema
  • blurred vision
  • photophobia
  • hearing loss
  • hematuria
  • increased uric acid levels
  • elevated serum potassium and phosphorus
  • hair loss
  • sleep disorders
  • memory loss
  • depression
  • interstitial lung disease
  • sexual dysfunction
  • diabetes
  • immune-mediated necrotizing myopathy
  • facial edema
  • arm edema
  • hypersensitivity
  • skin paresthesia
  • increased blood pressure
  • chest discomfort
  • upper respiratory infection
  • pharyngitis
  • sinusitis
  • cough
  • phlegm
  • runny nose
  • limb pain
  • congestive heart failure
  • myocardial ischemia
  • flushing
  • hypoglycemia
  • anemia
  • splenomegaly
  • hyperhidrosis
  • conjunctival congestion
  • renal failure
  • abnormal liver function
  • increased serum creatinine
  • elevated blood urea
  • abnormal liver function tests
  • anaphylaxis
  • rash
  • angioedema
  • erythema multiforme
  • pancreatitis
  • cholelithiasis
  • cholecystitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in an opaque container. Additionally, to ensure safe storage, it is advisable to keep it at a temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.